REVIEW



sin, Madison Cam Department of Pathology and, Wiley Online Library on [21/12/2022]. See the Terms and Conditions (https://onlinelibrary.wiley

conditions) on Wiley Online Library for rules of use; OA articles

are

governed by the applicable Creative

doi/10.1002/cam4.5545 by Unive

Breast cancer risk for women with diabetes and the impact of metformin: A meta-analysis

Yifan Lu¹ | Ali Hajjar² | Vincent L. Cryns³ | Amy Trentham-Dietz⁴ | Ronald E. Gangnon⁵ | Brandy M. Heckman-Stoddard⁶ | Oguzhan Alagoz⁷

¹Department of Industrial and Systems Engineering, University of Wisconsin-Madison, Madison, Wisconsin, USA

²Massachusetts General Hospital Institute for Technology Assessment, Harvard Medical School, Boston, Massachusetts, USA

³Department of Medicine, University of Wisconsin Carbone Cancer Center, University of Wisconsin-Madison, Madison, Wisconsin, USA

⁴Department of Population Health Sciences and the Carbone Cancer Center, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, USA

⁵Departments of Biostatistics & Medical Informatics and Population Health Sciences, University of Wisconsin-Madison, Madison, Wisconsin, USA

⁶Division of Cancer Prevention of the National Cancer Institute, Bethesda, Maryland, USA

⁷Department of Industrial and Systems Engineering and Department of Population Health Sciences, University of Wisconsin-Madison, Madison, Wisconsin, USA

Correspondence

Oguzhan Alagoz, University of Wisconsin-Madison, 1513 University Avenue, Madison, WI 53706, USA. Email: alagoz@engr.wisc.edu

Funding information

National Cancer Institute, Grant/Award Number: P30 CA014520 and U01 CA253911

Abstract

Background: Diabetes mellitus has been associated with increased breast cancer (BC) risk; however, the magnitude of this effect is uncertain. This study focused on BC risk for women with type 2 diabetes mellitus (T2DM).

Methods: Two separate meta-analyses were conducted (1) to estimate the relative risk (RR) of BC for women with T2DM and (2) to evaluate the risk of BC for women with T2DM associated with the use of metformin, a common diabetes treatment. In addition, subgroup analyses adjusting for obesity as measured by body mass index (BMI) and menopausal status were also performed. Studies were identified via PubMed/Scopus database and manual search through April 2021.

Results: A total of 30 and 15 studies were included in the first and second metaanalyses, respectively. The summary RR of BC for women with T2DM was 1.15 (95% confidence interval [CI], 1.09-1.21). The subgroup analyses adjusting BMI and adjusting BMI and menopause resulted in a summary RR of 1.22 (95% CI, 1.15-1.30) and 1.20 (95% CI, 1.05-1.36), respectively. For women with T2DM, the summary RR of BC was 0.82 (95% CI, 0.60-1.12) for metformin users compared with nonmetformin users.

Conclusions: Women with T2DM were more likely to be diagnosed with BC and this association was strengthened by adjusting for BMI and menopausal status. No statistically significant reduction of BC risk was observed among metformin users.

Impact: These two meta-analyses can inform decision-making for women with type 2 diabetes regarding their use of metformin and the use of screening mammography for early detection of breast cancer.

KEYWORDS

breast cancer, diabetes, meta-analysis, metformin, type 2 diabetes

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2022 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.

1 | INTRODUCTION

Over 15 million American women have type 2 diabetes mellitus (hereafter referred to as type 2 diabetes) and this figure is projected to increase in the future.¹ Type 2 diabetes increases the risk of other diseases including nephropathy, cardiovascular diseases, and retinopathy as well as cancer.²⁻⁵ In particular, diabetes is recognized as an independent risk factor for breast cancer.⁶⁻⁹

Many potential pathways have been suggested to explain the association between type 2 diabetes and breast cancer risk. For instance, type 2 diabetes is a chronic inflammatory disorder and is associated with inflammatory cell infiltrations, commonly seen in adipose tissue, which might lead to an increase in aromatase expression and increased local estrogen production. Increased estrogen production may drive the growth of estrogen receptor-positive (ER+) breast cancer.¹⁰ Another biological link is hyperinsulinemia, a condition that occurs due to the body's resistance to the effects of insulin in the blood and the pancreas attempts to compensate for the lack of insulin by producing increasingly more insulin. Hyperinsulinemia is a risk factor for type 2 diabetes.¹¹ Independent of obesity, alcohol consumption, physical inactivity, family history of breast cancer, history of benign breast disease, reproductive factors, and age, insulin resistance and hyperinsulinemia which are highly associated with diabetes have been identified as risk factors for breast cancer.⁶⁻⁹

Three peer-reviewed meta-analysis studies, all published prior to 2012, examined the relationship between breast cancer risk and diabetes (type 1, type 2, or gestational diabetes). All three studies found that women with diabetes had an increased risk of breast cancer (reported relative risk [RR]: 1.20, 1.23, and 1.27).¹²⁻¹⁴

The objective of the first part of the present study is to estimate the risk of breast cancer only for women with type 2 diabetes. The objective of the second meta-analysis in the present study is to estimate the breast cancer risk for women with type 2 diabetes associated with metformin use. Subgroup analyses with a focus on menopausal status and obesity had been planned depending on the availability of data.^{15,16} A total of eight new studies published since prior meta-analyses were included in our analysis. Moreover, while previous meta-analyses included all types of diabetes including type 1 and type 2 diabetes, we focused solely on type 2 diabetes to ensure that our results are not confounded. This is crucial because type 1 diabetes is caused by autoimmune destruction of the islets and resulting insulin deficiency,¹⁷ whereas type 2 diabetes is linked to insulin resistance, inflammation, and high insulin levels,¹⁸ which drive the initiation and progression of cancers.6,8,9

The objective of the second meta-analysis in the present study is to estimate the breast cancer risk for women with type 2 diabetes associated with metformin use. Subgroup analyses with a focus on menopausal status and obesity had been planned depending on the availability of data. Metformin is commonly prescribed to adults with type 2 diabetes, and around 40% of adults with type 2 diabetes in the USA take metformin as a treatment.¹⁹ Metformin has been suggested to inhibit cellular proliferation and tumor growth.²⁰⁻²² Combined, these two meta-analyses can inform decision-making for women with type 2 diabetes regarding their use of metformin and the use of screening mammography for early detection of breast cancer.

2 | MATERIALS AND METHODS

Following the guidance in the Cochrane Handbook,²³ we estimated the RR for breast cancer for women with type 2 diabetes compared with those without diabetes and the RR for breast cancer for women with type 2 diabetes associated with metformin use. Subgroup analyses with a focus on menopausal status and obesity were planned depending on the availability of the data.

2.1 | Search strategy

We searched the PubMed and Scopus databases through April 2021 for studies published in English using the search terms summarized in Table S1. Additional studies were identified through a manual search of references of review papers^{12,13,14,24,25} published after 2010.

2.2 | Study selection

The meta-analysis for the RR for breast cancer for women with type 2 diabetes compared with women without diabetes included (1) any observational study reporting an odds ratio (OR), RR, or hazard ratio (HR) estimate with a 95% confidence interval (CI), and (2) for females diagnosed with type 2 diabetes (or diagnosed at age \geq 30 if the type of diabetes was not specified). We used 30 as an age cutoff which is a common age cutoff to distinguish type 2 from type 1 diabetes in previous studies.²⁶⁻²⁸

The meta-analysis for the RR of breast cancer for women with type 2 diabetes associated with metformin use included (1) any observational study reporting an OR, RR, or HR estimate with 95% CI, (2) comparing metformin users to average nonmetformin users, and (3) included studies of females diagnosed with type 2 diabetes (or diagnosed at age \geq 30 if the type of diabetes was not specified).

Two independent investigators (Y.L. and A.H.) identified eligible studies by screening titles and abstracts. Disagreements related to the selection of the studies were resolved by a consensus decision after discussion.

2.3 Data extraction and quality assessment

Two investigators (Y.L. and A.H.) independently reviewed the selected studies and extracted the relevant information including full citation (authors, year of publication), geographic location of participant recruitment, age of the study population, adjustment of covariates, risk estimate, and the corresponding 95% CI. When one study reported multiple HRs, RRs, or ORs, the estimate adjusted for the highest number of covariates (first priority) for the longest duration of follow-up was used (second priority). When multiple publications used the same cohort, only the result from the most recent publication was included, and if the previous publications reported the results by adjusting for different sets of covariates, they were used in the subgroup analysis.

Two investigators (Y.L. and A.H.) independently evaluated the study quality using the Newcastle-Ottawa Assessment scale, an assessment for observational studies, in terms of selection, comparability, and exposure for cohort studies and selection, comparability, and outcomes for casecontrol studies.²⁹ Each study was assigned a score ranging from 0 to 9 with higher scores indicating higher quality. Each cohort study was judged on four items related to selection (representativeness of exposed cohort, selection of nonexposed cohort, ascertainment of exposure, and demonstration of outcome not presented at start), one item related to comparability (control for other confounding factors), and three items related to exposure (assessment of outcome, enough length for follow-up and adequacy of follow-up cohorts). A cohort study could be assigned one point for each item in selection and exposure categories and two points in comparability. Each case-control study was judged on four items related to selection (definition of cases, definition of controls representativeness of the cases, and selection of controls), one item related to comparability (control for other confounding factors), and three items related to outcome (assessment of outcome, same analysis method for cases and controls, and nonresponse rates). A case-control study could be assigned one point for each item in the selection and outcome categories and two points in comparability.²⁹

2.4 Statistical analysis

All extracted data were analyzed by Revman5 and MedCalc.^{30,31} Summary risk estimates were obtained using a random effects model with the inverse variance method. The I^2 test was used to evaluate heterogeneity across studies, where the recommended categories are set as possibly not important for $I^2 = 0\%-40\%$; moderate for $I^2 = 30\%-$ 60%; substantial for $I^2 = 50\%$ -90%; and considerable for $I^2 = 70\% - 100\%$ ²³ Subgroup analyses were performed for further investigation of the RR for women with type 2 diabetes. Two subgroups were created to investigate the factors of obesity and menopausal status. Furthermore, we summarized the estimates for pre- and postmenopausal women separately. When the studies included estimates stratified by menopausal status, we used those estimates for subgroup analysis instead of the overall estimates. Funnel plots along with Egger's test were used to assess potential publication bias. An asymmetric funnel plot will indicate a risk of publication bias, and this is further verified by Egger's test with a *p* value of < 0.05.^{23,26,32}

3 RESULTS

The relative risk of breast cancer 3.1 according to type 2 diabetes

Of 3,161 possible studies identified through database search, 34 relevant studies of the effect of type 2 diabetes on breast cancer were found after screening abstracts and titles, and any nonobservational study was excluded during this process. Two additional studies^{33,34} were found through a manual search of references in other review papers.¹²⁻¹⁴ After assessing the eligibility of each study according to our inclusion criteria, we included a total of 30 studies for analysis. Among the 30 studies, two studies^{35,36} used the same cohort. Since one of them adjusted for menopausal status and BMI,³⁶ we used one of them in estimating the overall effect, and the other one in the subgroup analysis. Figure 1 describes the screening and selection process. The characteristics of each study were summarized in Table 1.

The quality of the included studies was moderate with an average score of 6 using the Newcastle-Ottawa Assessment scale. Of the 30 studies, 11 studies had high quality (scoring between 7 and 9); 16 studies had moderate quality (scoring between 5 and 6); and three studies had low quality (scoring below 4) (Table 1).

Considerable heterogeneity was observed among the included studies as the I^2 was 81%; and thus, the random effects model was used. A funnel plot was produced, and no obvious evidence of publication bias was observed as the *p* value was 0.34 from Egger's test (Figure S1).

The overall effect indicated that women with type 2 diabetes were more likely to have breast cancer (RR = 1.15; 95% CI, 1.09-1.21). The summary risk estimate using only the cohort studies (RR = 1.14; 95% CI, 1.08-1.20) was



FIGURE 1 Flow chart of the literature search process for the metaanalysis estimating the relative risk of breast cancer for women with type 2

consistent with that using only the case-control studies (RR = 1.21; 95% CI, 1.04–1.40) (Figure 2). Of the 29 studies included in this meta-analysis, six studies were conducted in Asia^{27,33,41,42,43,60} with a summary RR equal to 1.25 (95% CI, 1.03–1.52); two studies focused on Hispanic women^{47,50}; and one study focused on Asian-American women.⁴⁶ The summary RR was 1.13 (95% CI,1.07-1.20) for the rest of the studies conducted in Europe or North America (Figure S2).

included

3 161 studies

identified through

database search

A limited number of studies presented results according to race or ethnicity, and subgroup analyses were conducted using the 20 studies in which women were randomly sampled in European and North American countries. A slightly greater RR was observed among the seven studies that provided estimates adjusted for BMI (RR = 1.22; 95% CI, 1.15-1.30). For the three studies adjusting for BMI and menopausal status, the summary RR was 1.20 (95% CI, 1.05-1.36). Furthermore, some studies reported their estimates stratified by menopausal status. The summary RR was 1.07 (95% CI, 1.03-1.11) and 0.97 (95% CI, 0.88–1.07) for the risk of breast cancer associated with type 2 diabetes for post- and premenopausal women with diabetes, respectively (Table S2 and Figure S3).

The relative risk of breast cancer 3.2 according to the use of metformin

For the second meta-analysis, we identified 724 studies to estimate the risk of breast cancer according to metformin use for women with type 2 diabetes through a database search, and 17 studies were selected after screening abstracts and titles. One study²⁸ was added through a manual search of the bibliographies of recent reviews.^{28,61} After assessing the eligibility of each study, we included a total of 15 studies for the final analysis (Figure 3). The characteristics of each study were summarized in Table 2.

Considerable heterogeneity was identified among studies as the I^2 was 97%. Therefore, the random effects model was used in the analysis. A funnel plot was produced, and no obvious evidence of publication bias was observed as the *p* value was 0.65 from Egger's test (Figure S4).

The quality of the included studies was high with an average score of 7 using the Newcastle-Ottawa Assessment scale. Of the 15 studies, 11 studies had high quality, whereas four studies had moderate quality (Table 2).

The overall risk estimate of breast cancer risk associated with the use of metformin was 0.82 with substantial variation around this estimate (95% CI, 0.60-1.12) (Figure 4). The limited number of studies prevented a subgroup analysis.

4 DISCUSSION

Our analysis found that women with type 2 diabetes were more likely to have breast cancer (RR = 1.15; 95% CI, 1.09–1.21). A stronger association was observed after the adjustment of BMI or BMI and menopausal status

	relative risk of breast cancer for women with type 2 diabetes	
	stimating the	
•	cteristics of the studies included in the meta-analysis	
	TABLE 1 Chara	

Study	Geographic location	Study design	No. of cases	No. of controls	Age	RR/OR/HR	95% CI	Adjustment	Quality score
Adami et al. ³⁴	Sweden	Cohort	27,862	N/A	≥20	0.9	0.8 - 1.1	Age and sex	9
Steenland et al. ³⁷	NSA	Cohort	1,250	11,804	Avg = 60	1.4	0.7-2.78	Age, BMI, smoking, alcohol, income, physical activity, and menopausal status	×
Weiderpass et al. ³⁸	Sweden	Cohort	70,110	N/A	≥40	1.3	1.2 - 1.4	Age and sex	9
Wideroff et al. ³⁹	Denmark	Cohort	55,010	N/A	≥50	1.1	1.1 - 1.2	Age and sex	7
Baron et al. ⁴⁰	USA	Case-control	5,659	5,928	50-75	1.2	1-1.4	Age, state, age at first birth, BMI, family history of breast cancer, HRT use, menopausal status, age at menopause, OC use, parity, alcohol use	Q
Jee et al. ⁴¹	Korea	Cohort	21,056	270,157	30-95	1.51	1.26–1.8	Age, age squared, amount of smoking, and alcohol use	6
Inoue et al. ⁴²	Japan	Cohort	1,571	49,652	40-69	0.83	0.44–1.57	Age at baseline, study area, history of cerebrovascular disease, history of ischemic heart disease, smoking, ethanol intake, body mass index, leisure-time physical activity, green vegetable intake, and coffee intake	9
Khan et al. ⁴³	Japan	Cohort	1,544	31,949	40-79	1.27	0.51-3.14	Age, BMI, smoking, and drinking	4
Lipscombe et al. ⁴⁴	Canada	Cohort	73,796	391,714	55-59	1.08	1.00 - 1.15	Age	7
Sellers et al. ⁴⁵	SU	Cohort	403	5,725	≥18, Avg = 47	1.61	0.98-2.62	Age, BMI, family history of breast cancer, parity education, alcohol use, physical activity, oral contraceptive use, age at menarche, hormone replacement therapy	4
Wu et al. ⁴⁶	USA	Case-control	1,248	1,148	25-74	1.68	1.15-2.47	Age, BMI, menopausal status, race, and education	6
Rollison et al. ⁴⁷	USA	Case-control	330	2,193	≥15	1.06	0.8-1.32	Age at menopause, use of postmenopausal hormones, physical activity, and alcohol consumption	7
Hemminki et al. ⁴⁸	Sweden	Cohort	125,126	922,796	≥39	1.37	1.28 - 1.46	Age and sex	5
Chodick et al. ⁴⁹	Israel	Cohort	16,721	83,874	≥21, avg = 61	1	0.86–1.19	Age, region, SES level, use of healthcare services a year prior or index date, BMI, and history of cardiovascular diseases	Q
Sanderson et al. ⁵⁰	USA	Case-control	190	468	30-79	0.77	0.49–1.23	Menopausal status and mammography screening	Ŋ
Bowker et al. ⁵¹	Canada	Cohort	84,506	84,506	Avg = 61.8	1	0.9-1.11	Age, social economic status, number of physician visits, and year of diagnosis	6

20457534, 0, Downloaded from https://ulineibhary.wiley.conditioi/10.1002cenat.5545 by University of Wisconsin, Addison Cam Department of Pathology and, Wiley Online Library on [21/12/2022]. See the Terms and Conditions 0 thtps://ulineibhary.wiley.com/defarts are governed by the applicable Ceasive Commons License

TABLE 1 (Continued)

Quality score	б		8	6	٥	6	∞	7	7
Adjustment	Age, BMI, Age at menarche, Age at 1st pregnancy, live birth, abortion, breastfeeding duration, age at menopause, hormone replacement therapy	Age, study center study period, education, alcohol consumption, age at menarche, age at first birth, age at menopause, hormone replacement therapy use, and family history of Breast cancer	Age period, region, and BMI	Age, menopausal status, race, and BMI	Age, first-degree relative with breast cancer, benign breast disease, age at menarche, age at menopause, parity, age at first birth, education, number of months of breastfeeding, smoking, alcohol consumption, body mass index, physical activity, duration of use of estrogen alone, duration of use of estrogen alone, duration of use of estrogen progesterone, bilateral oophorectomy, and mammogram within 2 years of baseline; stratified according to age (10-year groups), hormone therapy trial randomization, dietary trial randomization, dietary trial randomization, women's Health Initiative extension, and race/ethnicity	Age, sex, and year of cancer diagnosis	Age, period, region, and BMI	Age	Age, region, education, patient history of cancer, BMI, cigarette smoking, alcohol drinking, and physical activity
95% CI	1.34–22.81	1.3–2.27	0.98 - 1.29	0.95 - 1.69	0.85-1.14	1.00 - 1.52	0.82-1.45	0.94 - 1.08	1.01–1.47
RR/OR/HR	5.53	1.33	1.12	1.27	66.0	1.24	1.09	1	1.21
Age	35-70	33-80	≥35	≥30	50-79	40-84	20-85	≥18	30-79
No. of controls	184	4,082	30,210	1,453	64,618	1,018,518	1,094	147,998	281,705
No. of cases	184	3,869	52,657	1,495	3,401	14,420	916	147,998	18,305
Study design	Case-control	Case-control	Cohort	Case-control	Cohort	Cohort	Case-control	Cohort	Cohort
Geographic location	Armenia	Italy and Swiss	UK	USA	USA	Italy	Spain	UK	China
Study	Khachatryan et al. ³³	Rosato et al. ⁵²	Redaniel et al. ⁵³	Cleveland et al. ⁵⁴	Chlebowski et al. ⁵⁵	Gini et al. ⁵⁶	Garcia-Esquinas et al. ⁵⁷	Bronsveld et al. ⁵⁸	Pan et al. ²⁷

	Quality score	Ŋ	٢
	Adjustment	Age and sex	Age, ethnicity, smoking status, alcohol intake, multivitamin use, physical activity, total energy, alternative healthy eating index, family history of diabetes, family history of cancer, endoscopy screening, fasting glucose screening, insulin use, oral hypoglycemic drug use, mammography screening, postmenopausal hormone use, and oral contraceptive use, BMI
	95% CI	1.17–1.31	1.17–1.37
	RR/OR/HR	1.24	1.26
	Age	≥40	30-75
	No. of controls	N/A	3,355,787
	No. of cases	78,823	13,077
	Study design	Cohort	Cohort
tinued)	Geographic location	USA	USA
TABLE 1 (Cont	Study	Linkeviciute- Ulinskiene et al. ⁵⁹	Hu et al. ³⁵

Note: Quality score based on Newcastle-Ottawa Assessment scale. Abbreviations: Avg. average; CI, confidence interval; HR, hazard ratio; OR, odds ratio. Cancer Medicine

(RR = 1.22; 95% CI, 1.15–1.30 and 1.20; 95% CI, 1.05–1.35, respectively). For women with type 2 diabetes, our metaanalysis suggested that metformin use was associated with a reduced risk of breast cancer although the variation around the risk estimate was large (RR = 0.82, 95% CI, 0.60–1.12).

We found three meta-analysis studies on the relationship between breast cancer risk and diabetes published since 2010. Note that while none of the three previous reviews considered a quality assessment for the included studies, we assigned a score to each study using Newcastle-Ottawa Assessment scale to represent its quality. This approach has led to a more reliable estimation of the RR. More specifically, three studies in our meta-analysis were evaluated as low quality,^{33,43,45} and these three studies had the minor effect on the overall estimate. The summary RR of breast cancer for women with type 2 diabetes was 1.14 (95% CI, 1.09–1.20) when these three studies were excluded.^{33,43,45}

The study published by Boyle et al.¹² included 40 studies. They found women with diabetes had a higher risk of breast cancer (RR = 1.27; 95% CI, 1.16-1.39), and the study population included female patients having type 1 or type 2 diabetes. The meta-analysis published by Hardefeldt et al.¹⁴ included 43 observational studies on female or male patients having type 1, type 2, or gestational diabetes. The summary RR was 1.20 (95% CI, 1.13-1.29), and evidence of publication bias was observed. These two studies included a larger number of studies compared to the present study since we focused on only type 2 diabetes, whereas they included studies focusing on all types of diabetes. The meta-analysis published by Liao et al. in 2011 included a total of 12 observational studies, some of which did not specify the type of diabetes. The summary RR was 1.23 (95% CI, 1.18–1.27).¹³ In addition to these three peer-reviewed publications, we found a conference presentation from Bota et al.,⁷³ which reported a summary RR of 1.13 (95% CI, 1.04-1.24). No details on the selected studies were provided in this presentation.

The overall estimates on summary RR from the three meta-analyses are higher than our summary RR estimate as we limited the study population to female patients with only type 2 diabetes. A subgroup analysis on women with only type 2 diabetes by Boyle et al.¹² including 14 studies reported an RR of 1.16 (95% CI, 1.04–1.29), which is consistent with our estimate, and all of those 14 studies were included in our analysis. They also found that the association was stronger when only studies published after 1997 were included in the meta-analysis.¹² Another subgroup analysis on type 2 diabetes was conducted by Hardefeldt et al.,¹³ with 10 studies all published after 1997, reported an RR of 1.22 (95% CI, 1.07–1.40), and all these studies were included in our analysis. The trend was not obvious

				Risk Ratio		Risk Ratio
Study or Subgroup	log[Risk Ratio]	SE	Weight	IV, Random, 95% CI	Year	IV, Random, 95% CI
2.9.1 cohort						
Adami et al.1991	-0.1054	0.0812	3.9%	0.90 [0.77, 1.06]	1991	
Steenland et al. 1995	0.3365	0.3518	0.5%	1.40 [0.70, 2.79]	1995	
Weiderpass et al. 1997	0.2624	0.0393	5.5%	1.30 [1.20, 1.40]	1997	
Wideroff et al. 1997	0.0953	0.0222	6.0%	1.10 [1.05, 1.15]	1997	
Jee et al. 2005	0.4151	0.091	3.6%	1.51 [1.27, 1.81]	2005	
Inuoe et al. 2006	-0.1863	0.3245	0.6%	0.83 [0.44, 1.57]	2006	• • •
Khan et al. 2006	0.239	0.4367	0.3%	1.27 [0.54, 2.99]	2006	
Lipscombe et al. 2006	0.077	0.0357	5.6%	1.08 [1.01, 1.16]	2006	_ _
Sellers et al. 2007	0.4762	0.2508	0.9%	1.61 [0.98, 2.63]	2007	
Chlebowski et al. 2010	-0.01	0.0749	4.1%	0.99 [0.85, 1.15]	2010	
Chodick et al. 2010	0	0.0829	3.8%	1.00 [0.85, 1.18]	2010	
Hemminki et al. 2010	0.3148	0.0337	5.7%	1.37 [1.28, 1.46]	2010	
Bowker et al. 2011	0	0.0535	5.0%	1.00 [0.90, 1.11]	2011	
Hsieh et al. 2012	0.1053	0.0445	5.3%	1.11 [1.02, 1.21]	2012	_
Redaniel et al. 2012	0.1133	0.0701	4.3%	1.12 [0.98, 1.28]	2012	
Gini et al. 2016	0.2151	0.1068	3.1%	1.24 [1.01, 1.53]	2016	
Bronsveld et al. 2017	0	0.0354	5.7%	1.00 [0.93, 1.07]	2017	
Pan et al. 2018	0.1906	0.0957	3.4%	1.21 [1.00, 1.46]	2018	
Linkeviciute-Ulinskiene et al. 2019	0.2151	0.0288	5.9%	1.24 [1.17, 1.31]	2019	
Hu et al. 2020	0.2311	0.0403	5.5%	1.26 [1.16, 1.36]	2020	
Bjornsdottir et al. 2020	0.0488	0.0194	6.1%	1.05 [1.01, 1.09]	2020	
Subtotal (95% CI)			84.9%	1.14 [1.08, 1.20]		•
Heterogeneity: $Tau^2 = 0.01$; $Chi^2 = 1$.25.86, df = 20 (P	< 0.000	01); $I^2 = 3$	34%		
Test for overall effect: Z = 4.65 (P <	0.00001)					
2.9.2 case-control						
Baron et al. 2001	0 1823	0.0858	3 7%	1 20 [1 01 1 42]	2001	
Wu et al. 2007	0.1025	0 195	1 4%	1 68 [1 15 2 46]	2007	│ →
Rollison et al. 2010	0.0583	0 1277	2.5%	1.06 [0.83, 1.36]	2010	
Sanderson et al. 2010	-0.2614	0 2348	1.0%	0 77 [0 49 1 22]	2010	· · · · · · · · · · · · · · · · · · ·
khachatryan et al. 2011	1 7102	0 7231	0.1%	5 53 [1 34 22 82]	2011	│
Rosato et al 2011	0.2852	0 1422	2.2%	1 33 [1 01 1 76]	2011	
Cleveland et al. 2012	0 239	0 1469	2.1%	1 27 [0 95 1 69]	2012	
Garcia-Esquinas et al. 2016	0.0862	0 1454	2 1%	1 09 [0 82 1 45]	2016	
Subtotal (95% CI)	0.0002	0.1151	15.1%	1.21 [1.04, 1.40]	2010	
Heterogeneity: $Tau^2 = 0.02$; $Chi^2 = 1$	3.06, df = 7 (P =	0.07); I ²	= 46%			
Test for overall effect: $Z = 2.45$ (P =	0.01)					
Total (95% CI)			100.0%	1.15 [1.09, 1.21]		•
Heterogeneity: $Tau^2 = 0.01$ Chi ² = 1	40.26. df = 28 (P	< 0.000	$(01): ^2 = 3$	30%		
Test for overall effect: $Z = 5.33$ (P <	0.00001)		/, • _ •			0.5 0.7 1 1.5 2

Test for subgroup differences: $Chi^2 = 0.50$, df = 1 (P = 0.48), $I^2 = 0\%$

FIGURE 2 Summary of relative risk of breast cancer among women with type 2 diabetes according to study design (CI, confidence interval; IV, inverse variance; SE, standard error)

in our analysis as our analysis included only four studies published before 1997 (Figure S5). There are two possible reasons for this discrepancy. First, we included eight new studies^{27,35,53,56,57,59,74,75} having smaller risk estimates with a summary RR of 1.14 (95% CI, 1.05–1.24) and we only included studies on women with type 2 diabetes. Second, the use of metformin may inhibit the growth of certain tumors.²² Metformin is the most widely used oral medication for diabetes since the 1950s, and the extended release of metformin was approved in the USA in 2000.⁷⁶⁻⁷⁸ In the US, around 40% of diabetes patients use metformin as a treatment.¹⁹ Thus, the wide use of metformin might have also compromised the effect of diabetes mellitus on breast cancer risk.

Boyle et al.¹² and Liao et al.¹³ found postmenopausal women with diabetes had a 15% and 23% higher risk of breast cancer, respectively, while the association between

diabetes and breast cancer risk was closer to the null for premenopausal women.^{12,13} We observed the same trend in our analysis. Of the 20 studies, a total of 11 studies indicated the menopausal status of their study population, where five studies reported their estimates stratified by menopausal status and six studies were on postmenopausal women. The summary RR of breast cancer was 1.07 (95% CI, 1.03–1.11) and 0.94 (95% CI, 0.81–1.09) for post- and premenopausal women with diabetes, respectively (Table S2 and Figure S5). However, the determination for pre- and postmenopausal status varies among the studies we included. Some studies used simple age cutoff to separate pre- and postmenopausal groups, whereas others used menstrual data to define a woman as postmenopausal if she reported no cycles within 12 months.

Obesity is a confounding factor for the association between diabetes and the risk of breast cancer.¹⁶ In 2018,



around 90% of patients with diabetes were overweight or obese in the USA.¹ We conducted a subgroup analysis to account for the effect of obesity. Of the 20 studies in the meta-analysis, seven studies adjusting breast cancer risk for BMI resulted in a summary RR of 1.22 (95% CI, 1.15-1.30). Boyle et al.¹² and Hardefeldt et al.¹⁴ conducted a subgroup analysis with the studies that adjusted for BMI and found that the summary RR were 1.16 (95% CI, 1.08–1.24) and 1.12 (95% CI, 1.04-1.21), respectively. We observed a stronger association among the studies that adjusted for BMI. The association was also stronger than our overall estimate. In the present seven studies adjusting for BMI, six of them either included predominately postmenopausal women or had a study population with an average age over 50. Therefore, the study population in seven studies consisted of mostly older and postmenopausal women, leading to a higher RR in the subgroup analysis among the studies that included BMI. This is likely because studies of the risk of breast cancer and obesity have generally observed an increased risk of breast cancer for overweight and premenopausal women.⁷⁹ Furthermore, as noted by the study by Boyle et al.,¹² various methods of adjustment for BMI were used within the studies included in the meta-analysis. Most of the studies that were included in our analysis did not state how they parameterized BMI for adjustment in their statistical model.

There are some limitations to our analysis. In addition to obesity, menopausal status is another factor that might affect the final estimate.¹⁵ In the subgroup analysis, although we suspect both BMI and menopausal status can impact the RR of breast cancer for women with

type 2 diabetes, only three studies adjusted for BMI and menopausal status. Thus, the reliability of our estimate when both BMI and menopausal status were adjusted was compromised by the limited number of included studies. Considerable heterogeneity was observed among studies, and this might be largely caused by the differences in adjustment for confounding variables among studies. Furthermore, although no strong indication of publication bias was observed from the funnel plot and Egger's test, the actual RR might be higher than we observed as diabetes is still an under-diagnosed disease.¹

We also did not account for the differences in mammography screening utilization between women with and without diabetes. We do not expect the control on mammography screening utilization would affect our results. This is because although women with diabetes have higher healthcare utilization than women without diabetes, the complexity of diabetes care often decreases the rates of mammography screening for women with diabetes.⁸⁰⁻⁸⁴ For the 30 studies in our analysis, only three studies adjusted for the effect of mammography screening.^{35,50,55} Lack of control for mammography screening utilization may have led to the underestimation of the RR of cancer since women with diabetes who have existing breast cancer at the time of the study may not have been diagnosed due to lower rates of screening. This was further verified by the differences in the results from case-control studies and cohort studies. A stronger effect was observed among case-control studies, while cohort studies, especially those with long follow-up, may be vulnerable to the screening bias and led to an overall lower estimate.

TABLE 2 Char	acteristics of the s	studies included	in the meta	-analysis esti	mating the re	elative risk of brea	ist cancer for v	vomen with type 2 diabetes who use metformin	
Study	Geographic location	Study design	No. of cases	No. of controls	Age	RR/OR/HR	95% CI	Adjustment	Quality score
Libby et al. ²⁸	UK	Cohort	4,085	4,085	35-100	0.60	0.32-1.1	Age, smoking, deprivation, BMI, A1C, insulin use, and sulfonylurea use	9
Bodmer et al. ⁶²	UK	Case-control	305	1,153	30-79	0.42	0.21-0.77	Age, sex, general practice, and calendar time by matching and further adjusted for each other plus the use of prandial glucose regulators, acarbose, estrogens, smoking, BMI, diabetes duration, and A1C	×
Morden et al. ⁶³	NSA	Cohort	15,286	66,395	≥68	1.28	1.05 - 1.57	N/A	9
Bosco et al. ⁶⁴	Denmark	Case-control	1,250	3,073	≥50	0.83	0.56-1.22	Confounding and selection bias were introduced by matching on the county, and complications due to diabetes, clinical obesity, age at index date, and postmenopausal hormone use	∞
Chlebowski et al. ⁵⁵	USA	Cohort	3,401	64,618	50-79	0.75	0.57-0.99	Age, first-degree relative with breast cancer, benign breast disease, age at menarche, age at menopause, parity, age at first birth, education, number of months of breastfeeding, smoking, alcohol consumption, body mass index, physical activity, duration of use of estrogen alone, duration of use of estrogen plus progesterone, bilateral oophorectomy, and mammogram within 2 years of baseline; stratified according to age (10-year groups), hormone therapy trial randomization, dietary trial randomization or overall survival enrollment, ertollment onto Women's Health Initiative extension, and race/ethnicity	٥
Redaniel et al. ⁵³	UK	Cohort	52,657	30,210	≥35	1.02	0.79-1.3	Age, region and BMI	∞
Tseng et al. ⁶⁵	Taiwan	Cohort	191,195	285,087	Avg = 57	0.28	0.25-0.31	Age and obesity	8

Study	Geographic location	Study design	No. of cases	No. of controls	Age	RR/OR/HR	95% CI	Adjustment	Quality score
Chen et al. ⁶⁶	Taiwan	Cohort	2,223	5,102	≥30	0.8	0.3-2.13	Age, sex, Charlson comorbidity index, smoking-related comorbidities, alcohol use disorders, morbid obesity, pancreatitis, hypertension, monthly income, and urbanization level	٢
Soffer et al. ⁶⁷	SU	Cohort	4,887	61,891	18–103	1.08	0.88-1.32	Age of index diabetes diagnosis, race/ethnicity, ERT status, statin use, Charlson comorbidity index, and outpatient utilization	L
Garcia-Esquinas et al. ⁵⁷	Spain	Case-control	916	1,094	20-85	0.95	0.86-1.04	Age, period, region, and BMI	×
Calip et al. ⁶⁸	SU	Cohort	10,050	9,749	≥40	1.14	0.68-1.91	Other diabetes medications, age at cohort entry, study entry year, smoking status, menopausal status, Charlson score, and statin	×
Vicentini et al. ⁶⁹	Italy	Cohort	7,460	9,566	20-84	0.69	0.32-1.48	N/A	7
Hosio et al. ⁷⁰	Finland	Cohort	376,233	266,557	≥40	0.94	0.86 - 1.04	N/A	6
Dankner et al. ⁷¹	Isreal	Cohort	172,948	142,942	21-87	0.88	0.56-1.39	Age, sex, socioeconomic status, ethnic origin, smoking and parity.	×
Sung et al. ⁷²	Hongkong	Cohort	11,365	22,730	≥18	1.32	0.88-1.97	Age, sex, and comorbidities	7
ota: Ouality coora ha	sed on Nancastla-C	Accesement	ولوجع						

TABLE 2 (Continued)

Note: Quality score based on Newcastle-Ottawa Assessment scale.

Abbreviations: Avg. average; CI, confidence interval; HR, hazard ratio; OR, odds ratio.

Cancer Medicine



FIGURE 4 Summary of relative risk of breast cancer according to the use of metformin among women with type 2 diabetes (CI, confidence interval; IV, inverse variance; SE, standard error)

Two review studies examined the risk of breast cancer for women with type 2 diabetes associated with metformin use. The review by Tang et al.²⁴included 25 estimates from 12 observational studies up to November 2016, which found no significant association between metformin exposure and risk of breast cancer (RR = 0.93; 95% CI, 0.85-1.03). Multiple estimates were included from some studies in this review as these studies included results for several different types of glucose-lowering medicines. Of the total 12 studies, Currie et al.,⁶¹ Ruiter et al.,⁸⁵ Hsieh et al.,⁶⁰ Tsilidis et al.,⁸⁶ and Kowall et al.⁸⁷ were not included in the present study because their reference groups were sulfonylurea or insulin-based treatment users, while we only considered nonmetformin users as comparators as we suspect other glucose-lowering medicines may increase or decrease the risk of breast cancer.⁸⁸ Tang et al.²⁴ suggested the presence of publication bias based on their Egger's test.

Another study of the association between metformin use and breast cancer risk by Yang et al. included 11 estimates from nine studies, which reported a summary RR of 0.96 (95% CI, 0.76–1.22). Among the nine studies, Tsilidis et al.,⁸⁶ Qiu et al.,⁸⁹ and Hsieh et al.⁶⁰ were not included because their reference groups were either sulfonylurea or insulin-based treatment users. Three estimates from different durations of metformin use were included in the same study done by Bodmer et al. In this analysis, we only included the estimate for the longest duration of metformin use from Bodmer et al.⁶² Evidence of publication bias was also observed in this review article based on Egger's test.²⁵

Our meta-analysis included four additional studies published after 2016. However, similar to these studies, while we found a slightly lower summary RR (0.82; 95% CI, 0.60–1.12), the association was not statistically significant.

The summary estimate was highly driven by the estimate from Tseng et al.,⁶⁵ which is a large-scale study reporting the lowest HR with the smallest standard error and accounted for a weight of 7.6% in our analysis. After removing this study, the summary RR increased dramatically to 0.98 (95% CI, 0.89–1.07).

Unlike the previous reviews, no obvious evidence of publication bias among the studies was observed as the p value from Egger's test was 0.65. Although two prior reviews included estimates compared with other glucose-lowering medicines (sulfonylurea or insulinbased treatments), we only selected studies having nonmetformin users as the reference group. Furthermore, although Egger's test can be used to assess the asymmetry of funnel plots, it works better for continuous outcomes with intervention effects measured as mean differences.²³ Therefore, other possible reasons might affect the reliability of our results. As discussed above, obesity and menopausal status could serve as two confounding factors that may have affected our results. Unfortunately, we could not conduct subgroup analyses with a focus on obesity and menopausal status due to the limited number of studies. We found the baseline characteristics of the included metformin users were different across the included studies. Differences existed among the inclusion criteria for the minimum dose and length of use, and a stronger association was found among the few studies with a longer duration of metformin use. Another limitation of our study is that we cannot make a definite conclusion on the required dose of metformin to decrease the risk of developing breast cancer. This is because the studies included in this meta-analysis provide

little information on the dose of metformin and therefore the minimum dose of metformin likely varies across the studies. Metformin, as a treatment for type 2 diabetes, lowers blood glucose levels, and research shows that the antitumor effect of metformin depends on both glucose availability and metformin concentration.^{90,91} Among the studies we included, only two studies adjusted their results with hemoglobin A1C (a measure of glucose control) test results,^{28,62} and the majority did not. The cohort study from Libby et al.²⁸ included 4,085 cases and 4,085 controls, and the result did not show a statistically significant reduction of breast cancer risk associated with the use of metformin (RR = 0.60; 95% CI, 0.32–1.10). The case-control study from Bodmer et al.⁶² included 305 cases and 1,153 controls, and the result indicated a preventive effect of metformin on breast cancer (RR = 0.42; 95% CI, 0.21-0.77). The weights for these studies are relatively smaller compared with other studies in the calculation of the overall estimates because of their wide CIs. Therefore, we cannot make a definite conclusion based on these studies but suspect that blood glucose level could be another confounding factor affecting our estimates. In addition, patients who take metformin may also receive other glucose-lowering medicines, and there is no information on the number of such patients in most of the studies included in our meta-analysis, as other glucose-lowering medicines can serve as a confounding factor affecting our estimate of the risk of breast cancer.⁸⁸

Overall, obesity and menopausal status could serve as confounding factors that may have affected our results. However, a limited number of observational studies adjusted for these two factors, and thus, future work could examine the effects of these two factors. Also, based on the estimates from these two meta-analyses, another future research direction could be to optimize the decisionmaking for women with type 2 diabetes regarding their use of metformin and the use of screening mammography for early detection of breast cancer.

5 | CONCLUSION

Overall, we found women with type 2 diabetes were about 15% more likely to be diagnosed with breast cancer than women without type 2 diabetes. A stronger association (RR = 1.22) was observed after the adjustment of BMI and menopausal status. Metformin use was not associated with a statistically significant reduction in breast cancer risk.

DATA AVAILABILITY STATEMENT

Computer code: Available from Dr. Alagoz (email, alagoz@engr.wisc.edu). Analytic dataset: Available from Dr. Alagoz (email, alagoz@engr.wisc.edu).

__Cancer Medicine

AUTHOR CONTRIBUTIONS

Yifan Lu: Conceptualization (equal); formal analysis (lead); investigation (lead); methodology (lead); writing – original draft (lead). Ali Hajjar: Formal analysis (supporting); investigation (equal); validation (lead). Vincent Cryns: Resources (equal); writing – review and editing (equal). Amy Trentham-Dietz: Funding acquisition (equal); resources (equal); writing – review and editing (equal). Ronald E. Gangnon: Resources (equal); writing – review and editing (equal). Brandy Heckman-Stoddard: Writing – review and editing (supporting). Oguzhan Alagoz: Conceptualization (equal); funding acquisition (equal); project administration (lead); supervision (lead); writing – original draft (equal).

FUNDING INFORMATION

This work was supported by National Cancer Institute grants U01 CA253911 and P30 CA014520.

CONFLICT OF INTEREST

OA has been a paid consultant for Bristol Myers Squibb, Johnson & Johnson, and Exact Sciences, outside of the submitted work. No other conflicts to report.

ORCID

Oguzhan Alagoz https://orcid. org/0000-0002-5133-1382

REFERENCES

- National Diabetes Statistics Report. Centers for Disease Control and Prevention, U.S. Dept of Health and Human Services; 2020.
- 2. Gu K, Cowie CC, Harris MI. Diabetes and decline in heart disease mortality in US adults. *JAMA*. 1999;281(14):1291-1297.
- Molitch ME, DeFronzo RA, Franz MJ, et al. Nephropathy in diabetes. *Diabetes Care*. 2004;27(Suppl 1):S79-S83.
- 4. Wang W, Lo ACY. Diabetic retinopathy: pathophysiology and treatments. *Int J Mol Sci.* 2018;19(6):1816.
- Giovannucci E, Harlan DM, Archer MC, et al. Diabetes and cancer: a consensus report. *Diabetes Care*. 2010;33(7):1674-1685.
- Gunter MJ, Hoover DR, Yu H, et al. Insulin, insulin-like growth factor-I, and risk of breast cancer in postmenopausal women. J Natl Cancer Inst. 2009;101(1):48-60.
- 7. Esposito K, Chiodini P, Capuano A, et al. Metabolic syndrome and postmenopausal breast cancer: systematic review and meta-analysis. *Menopause*. 2013;20(12):1301-1309.
- Lawlor DA, Smith GD, Ebrahim S. Hyperinsulinaemia and increased risk of breast cancer: findings from the British Women's heart and health study. *Cancer Causes Control*. 2004;15(3):267-275.
- Sieri S, Muti P, Claudia A, et al. Prospective study on the role of glucose metabolism in breast cancer occurrence. *Int J Cancer*. 2012;130(4):921-929.
- Gallagher EJ, LeRoith D. The proliferating role of insulin and insulin-like growth factors in cancer. *Trends in Endocrinology & Metabolism.* 2010;21(10):610-618.
- 11. Weyer C, Funahashi T, Tanaka S, et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin

resistance and hyperinsulinemia. *J Clin Endocrinol Metabol.* 2001;86(5):1930-1935.

- 12. Boyle P, Boniol M, Koechlin A, et al. Diabetes and breast cancer risk: a meta-analysis. *Br J Cancer*. 2012;107(9):1608-1617.
- 13. Liao S, Li J, Wei W, et al. Association between diabetes mellitus and breast cancer risk: a meta-analysis of the literature. *Asian Pac J Cancer Prev.* 2011;12(4):1061-1065.
- Hardefeldt PJ, Edirimanne S, Eslick GD. Diabetes increases the risk of breast cancer: a meta-analysis. *Endocr Relat Cancer*. 2012;19(6):793-803.
- 15. Surakasula A, Nagarjunapu GC, Raghavaiah KV. A comparative study of pre- and post-menopausal breast cancer: risk factors, presentation, characteristics and management. *J Res Pharm Pract.* 2014;3(1):12-18.
- Picon-Ruiz M, Morata-Tarifa C, Valle-Goffin JJ, Friedman ER, Slingerland JM. Obesity and adverse breast cancer risk and outcome: mechanistic insights and strategies for intervention. *CA Cancer J Clin.* 2017;67(5):378-397.
- 17. Gillespie KM. Type 1 diabetes: pathogenesis and prevention. *Cmaj.* 2006;175(2):165-170.
- Chatterjee S, Khunti K, Davies MJ. Type 2 diabetes. *Lancet*. 2017;389(10085):2239-2251.
- Soric MM, Moorman JM, Boyle JA, Dengler-Crish CM. Prevalence and predictors of metformin prescribing in adults with type 2 diabetes mellitus: a National Cross-Sectional Study. *Pharmacotherapy*. 2016;36(7):715-722.
- 20. Alimova IN, Liu B, Fan Z, et al. Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro. *Cell Cycle*. 2009;8(6):909-915.
- Zakikhani M, Dowling R, Fantus IG, Sonenberg N, Pollak M. Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. *Cancer Res.* 2006;66(21):10269-10273.
- Zhang J, Li G, Chen Y, et al. Metformin inhibits tumorigenesis and tumor growth of breast cancer cells by upregulating miR-200c but downregulating AKT2 expression. *J Cancer*. 2017;8(10):1849-1864.
- 23. Higgins JPT, Thomas J, Chandler J, et al. *Cochrane Handbook for Systematic Reviews of Interventions*. 2nd ed. Wiley-Blackwell; 2019.
- Tang GH, Satkunam M, Pond GR, et al. Association of metformin with breast cancer incidence and mortality in patients with type II diabetes: a GRADE-assessed systematic review and meta-analysis. *Cancer Epidemiol Biomarkers Prev.* 2018;27(6):627-635.
- 25. Yang T, Yang Y, Liu S. Association between metformin therapy and breast cancer incidence and mortality: evidence from a meta-analysis. *J Breast Cancer*. 2015;18(3):264-270.
- Egger M, Davey Smith G, Schneider M, et al. Bias in metaanalysis detected by a simple, graphical test. *BMJ*. 1997;315(7109): 629-634.
- 27. Pan XF, He M, Yu C, et al. Type 2 diabetes and risk of incident cancer in China: a prospective study among 0.5 million Chinese adults. *Am J Epidemiol.* 2018;187(7):1380-1391.
- Libby G, Donnelly LA, Donnan PT, Alessi DR, Morris AD, Evans JMM. New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. *Diabetes Care*. 2009;32(9):1620-1625.
- 29. Wells GA, Shea B, O'Connell D, et al. *The Newcastle-Ottawa* Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses. Oxford; 2000.

- 30. Review Manager Web (Revman Web). The Cochrane Collaboration 2020.
- MedCalc Statistical Software version 19.2.6. 2020. https://www. medcalc.org
- 32. Au Yeung SL, Schooling CM. Impact of glycemic traits, type 2 diabetes and metformin use on breast and prostate cancer risk: a mendelian randomization study. *BMJ Open Diabetes Res Care*. 2019;7(1):e000872.
- Khachatryan L, Scharpf R, Kagan S. Influence of diabetes mellitus type 2 and prolonged estrogen exposure on risk of breast cancer among women in Armenia. *Health Care Women Int.* 2011;32(11):953-971.
- Adami HO, McLaughlin J, Ekbom A, et al. Cancer risk in patients with diabetes mellitus. *Cancer Causes Control*. 1991;2(5):307-314.
- 35. Hu Y, Zhang X, Ma Y, et al. Incident type 2 diabetes duration and cancer risk: a prospective study in two US cohorts. *J Na Cancer Institute*. 2020;113(4):381-389.
- Michels KB, Solomon CG, Hu FB, et al. Type 2 diabetes and subsequent incidence of breast cancer in the Nurses' health study. *Diabetes Care*. 2003;26(6):1752-1758.
- Steenland K, Nowlin S, Palu S. Cancer incidence in the National Health and nutrition survey I. follow-up data: diabetes, cholesterol, pulse and physical activity. *Cancer Epidemiol Biomarkers Prev.* 1995;4(8):807-811.
- Weiderpass E, Gridley G, Persson I, Nyrén O, Ekbom A, Adami HO. Risk of endometrial and breast cancer in patients with diabetes mellitus. *Int J Cancer*. 1997;71(3):360-363.
- Wideroff L, Gridley G, Mellemkjaer L, et al. Cancer incidence in a population-based cohort of patients hospitalized with diabetes mellitus in Denmark. JNatl Cancer Inst. 1997;89(18):1360-1365.
- Baron JA, Weiderpass E, Newcomb PA, et al. Metabolic disorders and breast cancer risk (United States). *Cancer Causes Control*. 2001;12(10):875-880.
- Jee SH, Ohrr H, Sull JW, Yun JE, Ji M, Samet JM. Fasting serum glucose level and cancer risk in Korean men and women. *JAMA*. 2005;293(2):194-202.
- 42. Inoue M, Iwasaki M, Otani T, et al. Diabetes mellitus and the risk of cancer: results from a large-scale population-based cohort study in Japan. *Arch Intern Med.* 2006;166(17):1871-1877.
- Khan M, Mori M, Fujino Y, et al. Site-specific cancer risk due to diabetes mellitus history: evidence from the Japan collaborative cohort (JACC) study. *Asian Pac J Cancer Prev.* 2006;7(2):253-259.
- 44. Lipscombe LL, Goodwin PJ, Zinman B, McLaughlin JR, Hux JE. Diabetes mellitus and breast cancer: a retrospective population-based cohort study. *Breast Cancer Res Treat*. 2006;98(3):349-356.
- Sellers TA, Jensen LE, Vierkant RA, et al. Association of diabetes with mammographic breast density and breast cancer in the Minnesota breast cancer family study. *Cancer Causes Control*. 2007;18(5):505-515.
- Wu AH, Yu MC, Tseng CC, Stanczyk FZ, Pike MC. Diabetes and risk of breast cancer in Asian-American women. *Carcinogenesis*. 2007;28(7):1561-1566.
- 47. Rollison DE, Giuliano AR, Sellers TA, et al. Populationbased case-control study of diabetes and breast cancer risk in Hispanic and non-Hispanic white women living in US southwestern states. *Am J Epidemiol.* 2008;167(4):447-456.

Cancer Medicine

- 48. Hemminki K, Li X, Sundquist J, Sundquist K. Risk of cancer following hospitalization for type 2 diabetes. *Oncologist*.
- 2010;15(6):548-555.
 49. Chodick G, Heymann AD, Rosenmann L, et al. Diabetes and risk of incident cancer: a large population-based cohort study in Israel. *Cancer Causes Control*. 2010;21(6):879-887.
- Sanderson M, Peltz G, Perez A, et al. Diabetes, physical activity and breast cancer among Hispanic women. *Cancer Epidemiol*. 2010;34(5):556-561.
- Bowker SL, Richardson K, Marra CA, Johnson JA. Risk of breast cancer after onset of type 2 diabetes: evidence of detection bias in postmenopausal women. *Diabetes Care*. 2011;34(12):2542-2544.
- 52. Rosato V, Bosetti C, Talamini R, et al. Metabolic syndrome and the risk of breast cancer in postmenopausal women. *Ann Oncol.* 2011;22(12):2687-2692.
- 53. Redaniel MT, Jeffreys M, May MT, et al. Associations of type 2 diabetes and diabetes treatment with breast cancer risk and mortality: a population-based cohort study among British women. *Cancer Causes Control.* 2012;23(11):1785-1795.
- Cleveland RJ, North KE, Stevens J, Teitelbaum SL, Neugut AI, Gammon MD. The association of diabetes with breast cancer incidence and mortality in the Long Island breast cancer study project. *Cancer Causes Control*. 2012;23(7):1193-1203.
- 55. Chlebowski RT, McTiernan A, Wactawski-Wende J, et al. Diabetes, metformin, and breast cancer in postmenopausal women. *J Clin Oncol*. 2012;30(23):2844-2852.
- 56. Gini A, Bidoli E, Zanier L, et al. Cancer among patients with type 2 diabetes mellitus: a population-based cohort study in northeastern Italy. *Cancer Epidemiol.* 2016;41:80-87.
- 57. García-Esquinas E, Guinó E, Castaño-Vinyals G, et al. Association of diabetes and diabetes treatment with incidence of breast cancer. *Acta Diabetol.* 2016;53(1):99-107.
- Bronsveld HK, Peeters P, de Groot MCH, et al. Trends in breast cancer incidence among women with type-2 diabetes in British general practice. *Prim Care Diabetes*. 2017;11(4):373-382.
- Linkeviciute-Ulinskiene D, Patasius A, Zabuliene L, Stukas R, Smailyte G. Increased risk of site-specific cancer in people with type 2 diabetes: a National Cohort Study. *Int J Environ Res Public Health*. 2019;17(1):246.
- Hsieh MC, Lee TC, Cheng SM, Tu ST, Yen MH, Tseng CH The influence of type 2 diabetes and glucose-lowering therapies on cancer risk in the Taiwanese. *Exp Diabetes Res* 2012;2012:1–6.
- 61. Currie CJ, Poole CD, Gale EA. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. *Diabetologia*. 2009;52(9):1766-1777.
- Bodmer M, Meier C, Krähenbühl S, Jick SS, Meier CR. Longterm metformin use is associated with decreased risk of breast cancer. *Diabetes Care*. 2010;33(6):1304-1308.
- 63. Morden NE, Liu SK, Smith J, Mackenzie TA, Skinner J, Korc M. Further exploration of the relationship between insulin glargine and incident cancer: a retrospective cohort study of older Medicare patients. *Diabetes Care*. 2011;34(9):1965-1971.
- Bosco JL, Antonsen S, Sørensen HT, et al. Metformin and incident breast cancer among diabetic women: a population-based case-control study in Denmark. *Cancer Epidemiol Biomarkers Prev.* 2011;20(1):101-111.
- Tseng CH. Metformin may reduce breast cancer risk in Taiwanese women with type 2 diabetes. *Breast Cancer Res Treat*. 2014;145(3):785-790.

66. Chen YC, Kok VC, Chien CH, Horng JT, Tsai JJ. Cancer risk in patients aged 30 years and above with type 2 diabetes receiving antidiabetic monotherapy: a cohort study using metformin as the comparator. *Ther Clin Risk Manag.* 2015;11:1315-1323.

-WILEY

- 67. Soffer D, Shi J, Chung J, et al. Metformin and breast and gynecological cancer risk among women with diabetes. *BMJ Open Diabetes Res Care*. 2015;3(1):e000049.
- Calip GS, Yu O, Elmore JG, Boudreau DM. Comparative safety of diabetes medications and risk of incident invasive breast cancer: a population-based cohort study. *Cancer Causes Control*. 2016;27(5):709-720.
- 69. Vicentini M, Ballotari P, Giorgi Rossi P, et al. Effect of different glucose-lowering therapies on cancer incidence in type 2 diabetes: an observational population-based study. *Diabetes Res Clin Pract.* 2018;143:398-408.
- Hosio M, Urpilainen E, Marttila M, et al. Association of antidiabetic medication and statins with breast cancer incidence in women with type 2 diabetes. *Breast Cancer Res Treat*. 2019;175(3):741-748.
- Dankner R, Agay N, Olmer L, et al. Metformin treatment and cancer risk: cox regression analysis, with time-dependent covariates, of 320,000 persons with incident diabetes mellitus. *Am J Epidemiol.* 2019;188(10):1794-1800.
- Sung JJ, Ho JM, Lam AS, et al. Use of metformin and aspirin is associated with delayed cancer incidence. *Cancer Epidemiol.* 2020;69:101808.
- 73. Bota M, Autier P, Boyle P. The risk of breast cancer in women with diabetes. *Diabetes*. 2018;67(Suppl. 1):180-OR.
- 74. Bronsveld HK, Jensen V, Vahl P, et al. Diabetes and breast cancer subtypes. *PLoS One*. 2017;12(1):e0170084.
- 75. Bjornsdottir HH, Rawshani A, Rawshani A, et al. A national observation study of cancer incidence and mortality risks in type 2 diabetes compared to the background population over time. *Sci Rep.* 2020;10(1):17376.
- 76. Fischer J, Ganellin CR. Analogue-based drug discovery. *Chem Int—Newsmagazine for IUPAC*. 2010;32(4):12-15.
- Flory J, Lipska K. Metformin in 2019. JAMA. 2019;321(19): 1926-1927.
- Le S, Lee GC. Emerging trends in metformin prescribing in the United States from 2000 to 2015. *Clin Drug Invest.* 2019;39(8):757-763.
- Munsell MF, Sprague BL, Berry DA, Chisholm G, Trentham-Dietz A. Body mass index and breast cancer risk according to postmenopausal estrogen-progestin use and hormone receptor status. *Epidemiol Rev.* 2014;36(1):114-136.
- Chan W, Yun L, Austin PC, et al. Impact of socioeconomic status on breast cancer screening in women with diabetes: a population-based study. *Diabet Med*. 2014;31(7):806-812.
- Lipscombe LL, Hux JE, Booth GL. Reduced screening mammography among women with diabetes. *Arch Intern Med.* 2005;165(18):2090-2095.
- McBean AM, Yu X. The underuse of screening services among elderly women with diabetes. *Diabetes Care*. 2007;30(6):1466-1472.
- Jiménez-Garcia R, Hernandez-Barrera V, Carrasco-Garrido P, Gil A. Prevalence and predictors of breast and cervical cancer screening among Spanish women with diabetes. *Diabetes Care*. 2009;32(8):1470-1472.

WILEY-Cancer Medicine

- Marshall JG, Cowell JM, Campbell ES, McNaughton DB. Regional variations in cancer screening rates found in women with diabetes. *Nurs Res.* 2010;59(1):34-41.
- 85. Ruiter R, Visser LE, van Herk-Sukel MP, et al. Lower risk of cancer in patients on metformin in comparison with those on sulfonylurea derivatives: results from a large population-based follow-up study. *Diabetes Care*. 2012;35(1):119-124.
- Tsilidis KK, Kasimis JC, Lopez DS, Ntzani EE, Ioannidis JPA. Type 2 diabetes and cancer: umbrella review of meta-analyses of observational studies. *BMJ*. 2015;350:g7607.
- 87. Kowall B, Stang A, Rathmann W, Kostev K. No reduced risk of overall, colorectal, lung, breast, and prostate cancer with metformin therapy in diabetic patients: database analyses from Germany and the UK. *Pharmacoepidemiol Drug Saf.* 2015;24(8):865-874.
- Pasello G, Urso L, Conte P, Favaretto A. Effects of sulfonylureas on tumor growth: a review of the literature. *Oncologist*. 2013;18(10):1118-1125.
- Qiu H, Rhoads GG, Berlin JA, Marcella SW, Demissie K. Initial metformin or sulphonylurea exposure and cancer occurrence among patients with type 2 diabetes mellitus. *Diabetes Obes Metab.* 2013;15(4):349-357.
- 90. Jones VC, Dietze EC, Jovanovic-Talisman T, McCune JS, Seewaldt VL. Metformin and chemoprevention: potential for

heart-healthy targeting of biologically aggressive breast cancer. *Front Public Health.* 2020;8:509714.

91. Sośnicki S, Kapral M, Węglarz L. Molecular targets of metformin antitumor action. *Pharmacol Rep.* 2016;68(5):918-925.

SUPPORTING INFORMATION

Additional supporting information can be found online in the Supporting Information section at the end of this article.

How to cite this article: Lu Y, Hajjar A, Cryns VL, et al. Breast cancer risk for women with diabetes and the impact of metformin: A meta-analysis. *Cancer Med.* 2022;00:1-16. doi:10.1002/cam4.5545